查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1786541

PET 放射性追踪剂市场：全球产业分析、规模、份额、成长、趋势及预测（2025-2032 年）

PET Radioactive Tracers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 350 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research 最近发布了一份关于全球 PET 放射性追踪剂市场的综合报告，该报告全面评估了关键市场动态，包括市场驱动因素、趋势、机会和挑战，并提供了有关市场结构的详细见解。

关键见解

  • PET放射性追踪剂市场规模（2025年）：10.698亿美元
  • 市场预测（2032年）：1,706,700,000
  • 全球市场成长率（2025-2032年复合年增长率）：6.9%

PET放射性追踪剂市场：研究范围

正子断层扫描 (PET) 放射性示踪剂是核子医学影像的关键组成部分，能够在分子层面上即时可视化生理过程。这些示踪剂主要以氟-18、碳-11和镓-68等同位素标记，广泛应用于肿瘤学、心臟病学、神经病学和其他领域。 PET 放射性追踪剂市场服务于医院、影像中心和研究机构，支援精准诊断、疾病分期、治疗监测和药物开发。市场成长的驱动力包括癌症和神经系统疾病的发病率不断上升、对先进成像模式的需求不断增长，以及 PET 成像在临床和临床前环境中的应用不断扩大。

市场驱动因素：

全球PET放射性追踪剂市场受到多种因素驱动，包括癌症和阿兹海默症慢性疾病负担的日益加重，这些疾病需要精确的早期诊断影像。 PET/CT和PET/MRI系统等混合成像技术的日益普及，进一步刺激了对示踪剂的需求。示踪剂开发的持续创新，包括针对特定受体和代谢途径的放射性药物，提高了诊断准确性并扩大了临床效用。此外，政府对分子影像研究的资助、已开发市场优惠的报销方案以及临床医生对PET临床益处的认识不断提高，都促进了PET市场的强劲成长。

市场限制：

儘管PET放射性示踪剂市场前景光明，但仍面临诸多限制因素。这些因素包括PET成像程序成本高昂，以及示踪剂半衰期短，因此需要接近性迴旋加速器设施并拥有可靠的放射性药物供应链。新型示踪剂的核准和生产存在监管障碍，以及处理和运输放射性物质的复杂物流，这些都为操作带来了挑战。此外，在资源匮乏的地区，PET影像的可及性有限，以及熟练核医专业人员的短缺，阻碍了PET影像的广泛应用，尤其是在新兴经济体。

市场机会：

受放射性示踪剂市场发展和放射性药物生产自动化技术进步的推动，PET放射性示踪剂市场正面临巨大的成长机会。用于免疫肿瘤学、心血管影像和神经退化性疾病监测的新型示踪剂的出现，正在拓展临床应用，并支持精准医疗方法。开发中国家PET影像设施的持续建立，加上官民合作关係改善放射性药物基础设施，带来了尚未开发的潜力。此外，製药公司与影像解决方案供应商合作开发用于标靶治疗的伴随诊断产品，也增强了市场前景。

本报告探讨的关键问题

  • 推动 PET 放射性追踪剂市场全球成长的关键因素有哪些？
  • 哪些同位素和临床应用正在推动成像中心对示踪剂的使用？
  • 法律规范与技术创新如何影响竞争格局？
  • PET 放射性追踪剂市场的主要企业是谁？他们采用了什么策略？
  • 追踪器开发和采用的新兴趋势和未来方向是什么？

目录

第一章执行摘要

第二章 市场概述

  • 市场范围/分类
  • 市场定义/范围/限制
  • 包含和排除

第三章：主要市场趋势

  • 影响市场的关键趋势
  • 创新/发展趋势

第四章：关键成功因素

  • PET扫描器部署场景
  • 各国 PET 扫描
  • 疾病流行病学
  • 产品采用/使用分析
  • 监理核准途径
  • 赎回情景
  • 技术进步
  • 良好生产规范 (cGMP)
  • 价值链分析
  • 品质标准/认证
  • PESTEL分析
  • 波特分析

第五章 市场背景

  • 宏观经济因素
  • 预测因子－相关性和影响力
  • 市场动态

第六章 COVID-19 危机分析

  • 2021 年市场情势
  • COVID-19 及其影响分析
    • 按产品
    • 按用途
    • 按最终用户
    • 按地区

第七章全球市场需求分析

  • 2019-2024年市场价值表现分析
  • 2025 年至 2032 年当前和未来市场价值预测
    • 年成长趋势分析
    • 绝对商机分析

第八章 世界市场产品分析

  • 简介/主要发现
  • 2019-2024 年各产品市场规模趋势分析
  • 2025 年至 2032 年按产品分類的当前和未来市场规模分析和预测
    • F-18
      • 氟倍他吡尔
      • 氟倍他班
      • 氟替米莫
      • 氟脱氧葡萄糖
      • 氟化钠
      • 其他的
    • C-11
      • 柯林
      • 甲硫胺酸
      • 其他的
    • Ga-68
      • DOTA-TOC
      • 多塔特
      • 多塔诺克
      • 其他的
    • O-15
    • N-13
    • Cu-64
  • 最终用户的市场吸引力分析

第九章 全球市场应用分析

  • 简介/主要发现
  • 2019-2024 年按应用分類的市场规模表现分析
  • 2025 年至 2032 年按应用分類的当前和未来市场规模分析与预测
    • 神经系统疾病
      • 阿兹海默症
      • 失智
      • 其他的
    • 癌症诊断和预后
      • 固态肿瘤
      • 血液系统肿瘤
    • 心臟功能障碍
      • 心肌梗塞
      • 其他的
    • 感染疾病诊断
    • 其他的
  • 最终用户的市场吸引力分析

第 10 章全球市场分析（按最终用户）

  • 简介/主要发现
  • 2019 年至 2024 年最终用户市场规模历史分析
  • 2025 年至 2032 年按最终用户分類的当前和未来市场规模分析和预测
    • 医院
    • 专业诊断中心
    • 癌症研究中心
    • 学术研究机构
  • 最终用户的市场吸引力分析

第十一章 世界市场区域分析

  • 介绍
  • 2019 年至 2024 年各地区市场规模历史分析
  • 2025 年至 2032 年各地区当前及未来市场规模分析及预测
    • 北美洲
    • 拉丁美洲
    • 东亚
    • 南亚和太平洋地区
    • 西欧
    • 东欧
    • 中亚
    • 俄罗斯和白俄罗斯
    • 巴尔干半岛和波罗的海国家
    • 中东和非洲
  • 区域市场吸引力分析

第十二章北美市场分析

第十三章：拉丁美洲市场分析

第十四章 东亚市场分析

第十五章南亚与太平洋市场分析

第十六章西欧市场分析

第十七章 东欧市场分析

第十八章：中亚市场分析

第十九章俄罗斯和白俄罗斯市场分析

20. 巴尔干半岛和波罗的海国家亚洲市场分析

第 21 章中东和非洲 (MEA) 市场分析

第22章市场结构分析

  • 按公司层级进行市场分析
  • 主要企业市场占有率分析
  • 市场影响分析

第23章 竞争分析

  • 竞争对手仪表板
  • 竞争基准
  • 衝突详情
    • Eli Lilly and Company
    • Blue Earth Diagnostics
    • Lantheus
    • Siemens Healthcare Private Limited
    • GE Healthcare
    • Advanced Accelerator Applications（Novartis）
    • University of Lowa HealthCare
    • Telix Pharmaceuticals Limited
    • Jubilant Radiopharma
    • TRASIS
    • RadioMedix Inc.
    • IBA Radiopharma Solutions
    • Piramal Imaging（Life Molecular Imaging）
    • Cardinal Health
    • DuchemBio, Co., Ltd

第 24 章：使用的假设与缩写

第25章调查方法

简介目录
Product Code: PMRREP33446

Persistence Market Research has recently released a comprehensive report on the worldwide market for PET radioactive tracers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • PET Radioactive Tracers Market Size (2025E): USD 1,069.8 Million
  • Projected Market Value (2032F): USD 1,706.7 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.9%

PET Radioactive Tracers Market - Report Scope:

Positron Emission Tomography (PET) radioactive tracers are critical components in nuclear medicine imaging, enabling real-time visualization of physiological processes at the molecular level. These tracers, primarily labeled with isotopes such as Fluorine-18, Carbon-11, and Gallium-68, are widely used for oncology, cardiology, and neurology applications. The PET radioactive tracers market serves hospitals, diagnostic imaging centers, and research institutions, supporting accurate diagnosis, disease staging, therapy monitoring, and drug development. Market growth is driven by the increasing prevalence of cancer and neurological disorders, rising demand for advanced imaging modalities, and the expanding use of PET imaging in clinical and preclinical settings.

Market Growth Drivers:

The global PET radioactive tracers market is propelled by several factors, including the growing burden of chronic diseases such as cancer and Alzheimer's disease, which require precise and early diagnostic imaging. The rising adoption of hybrid imaging technologies like PET/CT and PET/MRI systems further stimulates tracer demand. Continued innovation in tracer development, including radiopharmaceuticals targeting specific receptors and metabolic pathways, enhances diagnostic accuracy and broadens clinical utility. Moreover, government funding for molecular imaging research, favorable reimbursement scenarios in developed regions, and increasing awareness among clinicians regarding PET's clinical benefits contribute to robust market growth.

Market Restraints:

Despite a promising outlook, the PET radioactive tracers market faces several constraints. These include the high cost of PET imaging procedures and the short half-life of tracers, which necessitates proximity to cyclotron facilities and reliable radiopharmaceutical supply chains. Regulatory hurdles in the approval and production of new tracers, along with complex logistics for handling and transporting radioactive materials, create operational challenges. Additionally, limited access to PET imaging in low-resource settings and a shortage of skilled nuclear medicine professionals hinder widespread adoption, particularly in emerging economies.

Market Opportunities:

The PET radioactive tracers market presents significant growth opportunities fueled by technological advances in radiotracer development and automation in radiopharmacy. The emergence of novel tracers for immuno-oncology, cardiovascular imaging, and neurodegenerative disease monitoring expands clinical applications and supports precision medicine approaches. The increasing establishment of PET imaging facilities in developing countries, coupled with public-private partnerships to improve radiopharmaceutical infrastructure, offers untapped potential. Furthermore, collaborations between pharmaceutical companies and imaging solution providers to develop companion diagnostics for targeted therapies strengthen the market's future prospects.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the PET radioactive tracers market globally?
  • Which isotopes and clinical applications are driving tracer utilization across imaging centers?
  • How are regulatory frameworks and technological innovations shaping the competitive landscape?
  • Who are the key players in the PET radioactive tracers market, and what strategies are they adopting?
  • What are the emerging trends and future directions for tracer development and adoption?

Competitive Intelligence and Business Strategy:

These companies invest in R\&D to develop new fluorinated tracers, streamline synthesis procedures, and ensure regulatory compliance. Partnerships with academic institutions, pharmaceutical firms, and cyclotron manufacturers enhance tracer availability and support clinical research. Moreover, emphasis on automation, GMP-compliant production facilities, and distribution network expansion enables key players to maintain competitive advantage and meet the growing global demand.

Key Companies Profiled:

  • Eli Lilly and Company
  • Blue Earth Diagnostics
  • Lantheus
  • Siemens Healthcare Private Limited
  • GE Healthcare
  • Advanced Accelerator Applications (Novartis)
  • University of Lowa HealthCare
  • Telix Pharmaceuticals Limited
  • Jubilant Radiopharma
  • TRASIS
  • RadioMedix Inc.
  • IBA Radiopharma Solutions
  • Piramal Imaging (Life Molecular Imaging)
  • Cardinal Health
  • DuchemBio, Co. Ltd.

PET Radioactive Tracers Market Research Segmentation:

Product:

  • F-18
    • * Florbetapir
    • * Florbetaben
    • * Flutemetamol
    • * Fludeoxyglucose
    • * Sodium Fluoride
    • * Others
  • C-11
    • * Choline
    • * Methionine
    • * Others
  • Ga-68
    • * DOTA-TOC
    • * DOTATATE
    • * DOTANOC
    • * Others
  • O-15
  • N-13
  • Cu-64

Application:

  • Neurological Disorders
    • * Alzheimer's Disease
    • * Dementia
    • * Others
  • Cancer Diagnosis & Prognosis
    • * Solid Tumors
    • * Hematology Tumors
  • Cardiac Dysfunctions
    • * Myocardial Infarction
    • * Others
  • Infectious Disease Diagnosis
  • Others

End User:

  • Hospitals
  • Speciality Diagnostic Centers
  • Cancer Research Centers
  • Academic & Research Institutes

Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Western Europe
  • Eastern Europe
  • Central Asia
  • Russia & Belarus
  • Balkan & Baltic Countries
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. PET Scanner Installed Base Scenario
  • 4.2. Number of PET Scans, By Country
  • 4.3. Disease Epidemiology
  • 4.4. Product Adoption/Usage Analysis
  • 4.5. Regulatory Approval Pathway
  • 4.6. Reimbursement Scenario
  • 4.7. Technology Advancements
  • 4.8. Good Manufacturing Practice (cGMP)
  • 4.9. Value Chain Analysis
  • 4.10. Quality Standards/Accreditations
  • 4.11. PESTEL Analysis
  • 4.12. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Oncology Spending
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Development of Novel Products
    • 5.2.2. Regulatory Imposition
    • 5.2.3. Increasing Spending on Targeted Therapies
    • 5.2.4. Increasing Prevalence of Cancer
    • 5.2.5. Strategic Mergers and Acquisitions among Local Players
    • 5.2.6. Rising Awareness towards Development of Disease
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. 2021 Market Scenario
  • 6.2. COVID-19 and Impact Analysis
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Region

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2024 and Forecast, 2025-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2024
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2025-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019-2024
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2025-2032
    • 8.3.1. F-18
      • 8.3.1.1. Florbetapir
      • 8.3.1.2. Florbetaben
      • 8.3.1.3. Flutemetamol
      • 8.3.1.4. Fludeoxyglucose
      • 8.3.1.5. Sodium Fluoride
      • 8.3.1.6. Others
    • 8.3.2. C-11
      • 8.3.2.1. Choline
      • 8.3.2.2. Methionine
      • 8.3.2.3. Others
    • 8.3.3. Ga-68
      • 8.3.3.1. DOTA-TOC
      • 8.3.3.2. DOTATATE
      • 8.3.3.3. DOTANOC
      • 8.3.3.4. Others
    • 8.3.4. O-15
    • 8.3.5. N-13
    • 8.3.6. Cu-64
  • 8.4. Market Attractiveness Analysis By End User

9. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Application

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2019-2024
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2025-2032
    • 9.3.1. Neurological Disorders
      • 9.3.1.1. Alzheimer's Disease
      • 9.3.1.2. Dementia
      • 9.3.1.3. Others
    • 9.3.2. Cancer Diagnosis & Prognosis
      • 9.3.2.1. Solid Tumor
      • 9.3.2.2. Hematology Tumor
    • 9.3.3. Cardiac Dysfunctions
      • 9.3.3.1. Myocardial Infarction
      • 9.3.3.2. Others
    • 9.3.4. Infectious disease Diagnosis
    • 9.3.5. Others
  • 9.4. Market Attractiveness Analysis By End User

10. Global Market Analysis 2019-2024 and Forecast 2025-2032, By End User

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2024
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2025-2032
    • 10.3.1. Hospitals
    • 10.3.2. Speciality Diagnostic Centers
    • 10.3.3. Cancer Research Centers
    • 10.3.4. Academic & Research Institutes
  • 10.4. Market Attractiveness Analysis By End User

11. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2024
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025-2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. East Asia
    • 11.3.4. South Asia & Pacific
    • 11.3.5. Western Europe
    • 11.3.6. Eastern Europe
    • 11.3.7. Central Asia
    • 11.3.8. Russia & Belarus
    • 11.3.9. Balkan & Baltic Countries
    • 11.3.10. Middle East & Africa
  • 11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2019-2024 and Forecast 2025-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Product
    • 12.3.3. By Application
    • 12.3.4. By End User
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Product
    • 12.4.3. By Application
    • 12.4.4. By End User
  • 12.5. Key Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Market
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Product
        • 12.8.1.2.2. By Application
        • 12.8.1.2.3. By End User
    • 12.8.2. Canada Market
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Product
        • 12.8.2.2.2. By Application
        • 12.8.2.2.3. By End User

13. Latin America Market Analysis 2019-2024 and Forecast 2025-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Argentina
      • 13.3.1.3. Mexico
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Product
    • 13.3.3. By Application
    • 13.3.4. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Application
    • 13.4.4. By End User
  • 13.5. Key Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Brazil Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Application
        • 13.8.1.2.3. By End User
    • 13.8.2. Argentina Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Application
        • 13.8.2.2.3. By End User
    • 13.8.3. Mexico Market
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Product
        • 13.8.3.2.2. By Application
        • 13.8.3.2.3. By End User

14. East Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Product
    • 14.3.3. By Application
    • 14.3.4. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Application
    • 14.4.4. By End User
  • 14.5. Key Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Application
        • 14.8.1.2.3. By End User
    • 14.8.2. Japan Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Application
        • 14.8.2.2.3. By End User
    • 14.8.3. South Korea Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Application
        • 14.8.3.2.3. By End User

15. South Asia & Pacific Market Analysis 2019-2024 and Forecast 2025-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Thailand
      • 15.3.1.4. Philippines
      • 15.3.1.5. Malaysia
      • 15.3.1.6. Vietnam
      • 15.3.1.7. Rest of ASEAN
      • 15.3.1.8. Australia & New Zealand
    • 15.3.2. By Product
    • 15.3.3. By Application
    • 15.3.4. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Application
    • 15.4.4. By End User
  • 15.5. Key Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Application
        • 15.8.1.2.3. By End User
    • 15.8.2. Indonesia Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Application
        • 15.8.2.2.3. By End User
    • 15.8.3. Thailand Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Application
        • 15.8.3.2.3. By End User
    • 15.8.4. Philippines Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Application
        • 15.8.4.2.3. By End User
    • 15.8.5. Malaysia Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By Application
        • 15.8.5.2.3. By End User
    • 15.8.6. Vietnam Market
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Product
        • 15.8.6.2.2. By Application
        • 15.8.6.2.3. By End User
    • 15.8.7. Australia & New Zealand Market
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Product
        • 15.8.7.2.2. By Application
        • 15.8.7.2.3. By End User

16. Western Europe Market Analysis 2019-2024 and Forecast 2025-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 16.3.1. By Country
      • 16.3.1.1. Germany
      • 16.3.1.2. France
      • 16.3.1.3. Spain
      • 16.3.1.4. Italy
      • 16.3.1.5. BENELUX
      • 16.3.1.6. Nordic Countries
      • 16.3.1.7. United Kingdom
    • 16.3.2. By Product
    • 16.3.3. By Application
    • 16.3.4. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By Application
    • 16.4.4. By End User
  • 16.5. Key Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Germany Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Application
        • 16.8.1.2.3. By End User
    • 16.8.2. France Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Application
        • 16.8.2.2.3. By End User
    • 16.8.3. Spain Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Application
        • 16.8.3.2.3. By End User
    • 16.8.4. Italy Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Product
        • 16.8.4.2.2. By Application
        • 16.8.4.2.3. By End User
    • 16.8.5. BENULUX Market
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Product
        • 16.8.5.2.2. By Application
        • 16.8.5.2.3. By End User
    • 16.8.6. Nordic Countries Market
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Product
        • 16.8.6.2.2. By Application
        • 16.8.6.2.3. By End User
    • 16.8.7. U.K. Market
      • 16.8.7.1. Introduction
      • 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.7.2.1. By Product
        • 16.8.7.2.2. By Application
        • 16.8.7.2.3. By End User

17. Eastern Europe Market Analysis 2019-2024 and Forecast 2025-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 17.3.1. By Country
      • 17.3.1.1. Poland
      • 17.3.1.2. Hungary
      • 17.3.1.3. Romania
      • 17.3.1.4. Czech Republic
      • 17.3.1.5. Rest of Eastern Europe
    • 17.3.2. By Product
    • 17.3.3. By Application
    • 17.3.4. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Application
    • 17.4.4. By End User
  • 17.5. Key Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. Poland Market
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Product
        • 17.8.1.2.2. By Application
        • 17.8.1.2.3. By End User
    • 17.8.2. Hungary Market
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Product
        • 17.8.2.2.2. By Application
        • 17.8.2.2.3. By End User
    • 17.8.3. Romania Market
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Product
        • 17.8.3.2.2. By Application
        • 17.8.3.2.3. By End User
    • 17.8.4. Czech Republic Market
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Product
        • 17.8.4.2.2. By Application
        • 17.8.4.2.3. By End User

18. Central Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 18.3.1. By Product
    • 18.3.2. By Application
    • 18.3.3. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Product
    • 18.4.2. By Application
    • 18.4.3. By End User
  • 18.5. Key Market Trends
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Key Players - Intensity Mapping

19. Russia & Belarus Market Analysis 2019-2024 and Forecast 2025-2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 19.3.1. By Product
    • 19.3.2. By Application
    • 19.3.3. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Product
    • 19.4.2. By Application
    • 19.4.3. By End User
  • 19.5. Key Market Trends
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Key Players - Intensity Mapping

20. Balkan & Baltic Countries Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 20.1. Introduction
  • 20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 20.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 20.3.1. By Product
    • 20.3.2. By Application
    • 20.3.3. By End User
  • 20.4. Market Attractiveness Analysis
    • 20.4.1. By Product
    • 20.4.2. By Application
    • 20.4.3. By End User
  • 20.5. Key Market Trends
  • 20.6. Drivers and Restraints - Impact Analysis
  • 20.7. Key Players - Intensity Mapping

21. Middle East and Africa (MEA) Market Analysis 2019-2024 and Forecast 2025-2032

  • 21.1. Introduction
  • 21.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 21.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 21.3.1. By Country
      • 21.3.1.1. GCC Countries
      • 21.3.1.2. Kingdom of Saudi Arabia
      • 21.3.1.3. Turkiye
      • 21.3.1.4. Northern Africa
      • 21.3.1.5. South Africa
      • 21.3.1.6. Israel
    • 21.3.2. By Product
    • 21.3.3. By Application
    • 21.3.4. By End User
  • 21.4. Market Attractiveness Analysis
    • 21.4.1. By Country
    • 21.4.2. By Product
    • 21.4.3. By Application
    • 21.4.4. By End User
  • 21.5. Key Market Trends
  • 21.6. Drivers and Restraints - Impact Analysis
  • 21.7. Key Players - Intensity Mapping
  • 21.8. Country Level Analysis & Forecast
    • 21.8.1. GCC Countries Market
      • 21.8.1.1. Introduction
      • 21.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.1.2.1. By Product
        • 21.8.1.2.2. By Application
        • 21.8.1.2.3. By End User
    • 21.8.2. Kingdom of Saudi Arabia Market
      • 21.8.2.1. Introduction
      • 21.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.2.2.1. By Product
        • 21.8.2.2.2. By Application
        • 21.8.2.2.3. By End User
    • 21.8.3. Turkiye Market
      • 21.8.3.1. Introduction
      • 21.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.3.2.1. By Product
        • 21.8.3.2.2. By Application
        • 21.8.3.2.3. By End User
    • 21.8.4. Northern Africa Market
      • 21.8.4.1. Introduction
      • 21.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.4.2.1. By Product
        • 21.8.4.2.2. By Application
        • 21.8.4.2.3. By End User
    • 21.8.5. South Africa Market
      • 21.8.5.1. Introduction
      • 21.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.5.2.1. By Product
        • 21.8.5.2.2. By Application
        • 21.8.5.2.3. By End User
    • 21.8.6. Israel Market
      • 21.8.6.1. Introduction
      • 21.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.6.2.1. By Product
        • 21.8.6.2.2. By Application
        • 21.8.6.2.3. By End User

22. Market Structure Analysis

  • 22.1. Market Analysis by Tier of Companies
  • 22.2. Market Share Analysis of Top Players
  • 22.3. Market Presence Analysis
    • 22.3.1. Regional footprint of Players
    • 22.3.2. Platform Type foot print by Players
    • 22.3.3. Channel Foot Print by Players

23. Competition Analysis

  • 23.1. Competition Dashboard
  • 23.2. Competition Benchmarking
  • 23.3. Competition Deep Dive
    • 23.3.1. Eli Lilly and Company
      • 23.3.1.1. Company Overview
      • 23.3.1.2. Product Portfolio
      • 23.3.1.3. Sales Footprint
      • 23.3.1.4. Key Financials
      • 23.3.1.5. SWOT Analysis
      • 23.3.1.6. Key Developments
      • 23.3.1.7. Strategy Overview
        • 23.3.1.7.1. Channel Strategy
        • 23.3.1.7.2. Marketing Strategy
        • 23.3.1.7.3. Product Strategy
    • 23.3.2. Blue Earth Diagnostics
      • 23.3.2.1. Company Overview
      • 23.3.2.2. Product Portfolio
      • 23.3.2.3. Sales Footprint
      • 23.3.2.4. Key Financials
      • 23.3.2.5. SWOT Analysis
      • 23.3.2.6. Key Developments
      • 23.3.2.7. Strategy Overview
        • 23.3.2.7.1. Channel Strategy
        • 23.3.2.7.2. Marketing Strategy
        • 23.3.2.7.3. Product Strategy
    • 23.3.3. Lantheus
      • 23.3.3.1. Company Overview
      • 23.3.3.2. Product Portfolio
      • 23.3.3.3. Sales Footprint
      • 23.3.3.4. Key Financials
      • 23.3.3.5. SWOT Analysis
      • 23.3.3.6. Key Developments
      • 23.3.3.7. Strategy Overview
        • 23.3.3.7.1. Channel Strategy
        • 23.3.3.7.2. Marketing Strategy
        • 23.3.3.7.3. Product Strategy
    • 23.3.4. Siemens Healthcare Private Limited
      • 23.3.4.1. Company Overview
      • 23.3.4.2. Product Portfolio
      • 23.3.4.3. Sales Footprint
      • 23.3.4.4. Key Financials
      • 23.3.4.5. SWOT Analysis
      • 23.3.4.6. Key Developments
      • 23.3.4.7. Strategy Overview
        • 23.3.4.7.1. Channel Strategy
        • 23.3.4.7.2. Marketing Strategy
        • 23.3.4.7.3. Product Strategy
    • 23.3.5. GE Healthcare
      • 23.3.5.1. Company Overview
      • 23.3.5.2. Product Portfolio
      • 23.3.5.3. Sales Footprint
      • 23.3.5.4. Key Financials
      • 23.3.5.5. SWOT Analysis
      • 23.3.5.6. Key Developments
      • 23.3.5.7. Strategy Overview
        • 23.3.5.7.1. Channel Strategy
        • 23.3.5.7.2. Marketing Strategy
        • 23.3.5.7.3. Product Strategy
    • 23.3.6. Advanced Accelerator Applications (Novartis)
      • 23.3.6.1. Company Overview
      • 23.3.6.2. Product Portfolio
      • 23.3.6.3. Sales Footprint
      • 23.3.6.4. Key Financials
      • 23.3.6.5. SWOT Analysis
      • 23.3.6.6. Key Developments
      • 23.3.6.7. Strategy Overview
        • 23.3.6.7.1. Channel Strategy
        • 23.3.6.7.2. Marketing Strategy
        • 23.3.6.7.3. Product Strategy
    • 23.3.7. University of Lowa HealthCare
      • 23.3.7.1. Company Overview
      • 23.3.7.2. Product Portfolio
      • 23.3.7.3. Sales Footprint
      • 23.3.7.4. Key Financials
      • 23.3.7.5. SWOT Analysis
      • 23.3.7.6. Key Developments
      • 23.3.7.7. Strategy Overview
        • 23.3.7.7.1. Channel Strategy
        • 23.3.7.7.2. Marketing Strategy
        • 23.3.7.7.3. Product Strategy
    • 23.3.8. Telix Pharmaceuticals Limited
      • 23.3.8.1. Company Overview
      • 23.3.8.2. Product Portfolio
      • 23.3.8.3. Sales Footprint
      • 23.3.8.4. Key Financials
      • 23.3.8.5. SWOT Analysis
      • 23.3.8.6. Key Developments
      • 23.3.8.7. Strategy Overview
        • 23.3.8.7.1. Channel Strategy
        • 23.3.8.7.2. Marketing Strategy
        • 23.3.8.7.3. Product Strategy
    • 23.3.9. Jubilant Radiopharma
      • 23.3.9.1. Company Overview
      • 23.3.9.2. Product Portfolio
      • 23.3.9.3. Sales Footprint
      • 23.3.9.4. Key Financials
      • 23.3.9.5. SWOT Analysis
      • 23.3.9.6. Key Developments
      • 23.3.9.7. Strategy Overview
        • 23.3.9.7.1. Channel Strategy
        • 23.3.9.7.2. Marketing Strategy
        • 23.3.9.7.3. Product Strategy
    • 23.3.10. TRASIS
      • 23.3.10.1. Company Overview
      • 23.3.10.2. Product Portfolio
      • 23.3.10.3. Sales Footprint
      • 23.3.10.4. Key Financials
      • 23.3.10.5. SWOT Analysis
      • 23.3.10.6. Key Developments
      • 23.3.10.7. Strategy Overview
        • 23.3.10.7.1. Channel Strategy
        • 23.3.10.7.2. Marketing Strategy
        • 23.3.10.7.3. Product Strategy
    • 23.3.11. RadioMedix Inc.
      • 23.3.11.1. Company Overview
      • 23.3.11.2. Product Portfolio
      • 23.3.11.3. Sales Footprint
      • 23.3.11.4. Key Financials
      • 23.3.11.5. SWOT Analysis
      • 23.3.11.6. Key Developments
      • 23.3.11.7. Strategy Overview
        • 23.3.11.7.1. Channel Strategy
        • 23.3.11.7.2. Marketing Strategy
        • 23.3.11.7.3. Product Strategy
    • 23.3.12. IBA Radiopharma Solutions
      • 23.3.12.1. Company Overview
      • 23.3.12.2. Product Portfolio
      • 23.3.12.3. Sales Footprint
      • 23.3.12.4. Key Financials
      • 23.3.12.5. SWOT Analysis
      • 23.3.12.6. Key Developments
      • 23.3.12.7. Strategy Overview
        • 23.3.12.7.1. Channel Strategy
        • 23.3.12.7.2. Marketing Strategy
        • 23.3.12.7.3. Product Strategy
    • 23.3.13. Piramal Imaging (Life Molecular Imaging)
      • 23.3.13.1. Company Overview
      • 23.3.13.2. Product Portfolio
      • 23.3.13.3. Sales Footprint
      • 23.3.13.4. Key Financials
      • 23.3.13.5. SWOT Analysis
      • 23.3.13.6. Key Developments
      • 23.3.13.7. Strategy Overview
        • 23.3.13.7.1. Channel Strategy
        • 23.3.13.7.2. Marketing Strategy
        • 23.3.13.7.3. Product Strategy
    • 23.3.14. Cardinal Health
      • 23.3.14.1. Company Overview
      • 23.3.14.2. Product Portfolio
      • 23.3.14.3. Sales Footprint
      • 23.3.14.4. Key Financials
      • 23.3.14.5. SWOT Analysis
      • 23.3.14.6. Key Developments
      • 23.3.14.7. Strategy Overview
        • 23.3.14.7.1. Channel Strategy
        • 23.3.14.7.2. Marketing Strategy
        • 23.3.14.7.3. Product Strategy
    • 23.3.15. DuchemBio, Co., Ltd
      • 23.3.15.1. Company Overview
      • 23.3.15.2. Product Portfolio
      • 23.3.15.3. Sales Footprint
      • 23.3.15.4. Key Financials
      • 23.3.15.5. SWOT Analysis
      • 23.3.15.6. Key Developments
      • 23.3.15.7. Strategy Overview
        • 23.3.15.7.1. Channel Strategy
        • 23.3.15.7.2. Marketing Strategy
        • 23.3.15.7.3. Product Strategy

24. Assumptions and Acronyms Used

25. Research Methodology